Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors
Public ClinicalTrials.gov record NCT04972110. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1b/2 Study of ATR InhibiTor RP-3500 and PARP Inhibitor Combinations in Patients With Molecularly Selected Cancers (ATTACC)
Study identification
- NCT ID
- NCT04972110
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Repare Therapeutics
- Industry
- Enrollment
- 156 participants
Conditions and interventions
Conditions
Interventions
- RP-3500 (camonsertib) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 20, 2021
- Primary completion
- Nov 12, 2024
- Completion
- Nov 12, 2024
- Last update posted
- Oct 29, 2025
2021 – 2024
United States locations
- U.S. sites
- 13
- U.S. states
- 12
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Participating Site #1018 | Phoenix | Arizona | 97401 | — |
| Participating Site #1025 | San Francisco | California | 94158 | — |
| Participating Site #1028 | Aurora | Colorado | 80012 | — |
| Participating Site #1012 | New Haven | Connecticut | 06511 | — |
| Participating Site #1017 | Jacksonville | Florida | 32224 | — |
| Participating Site #1009 | Baltimore | Maryland | 21205 | — |
| Participating Site #1015 | Ann Arbor | Michigan | 48109 | — |
| Participating Site # 1016 | Rochester | Minnesota | 55905 | — |
| Participating Site #1026 | New York | New York | 10029 | — |
| Participating Site # 1008 | New York | New York | 10032 | — |
| Participating Site #1029 | Eugene | Oregon | 97401 | — |
| Participating Site # 1001 | Houston | Texas | 77030 | — |
| Participating Site # 1013 | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04972110, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 29, 2025 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04972110 live on ClinicalTrials.gov.